An Observational Study of NeoRecormon (Epoetin Beta) in Cancer Patients With Anemia (FAST)

Pharmaco-epidemiological Observational Study of the Clinical Benefit of NeoRecormon® in Cancer Patients With Anemia, According to Early Response to Treatment

This observational study will evaluate the clinical benefit of NeoRecormon (epoetin beta) in daily routine practice in cancer patients with anemia. Data will be collected from patients who are receiving chemotherapy for a solid tumor or hematological malignancy. Patients will be followed for 28 weeks.

Inclusion Criteria:

• Adult patients, >/=18 years of age
• Patients receiving myelosuppressive chemotherapy for a solid tumor, a hematological malignancy or an autograft for hematological malignancy
• Patients for whom treatment with epoetin beta is started at the inclusion visit
• Life expectancy >/=6 months according to the physician
• Patients accepting and able to complete a French written questionnaire about his/her professional and social activities at each visit

Exclusion Criteria:

• Patients who received erythropoiesis-stimulating agents treatment, or red blood cell transfusion within 4 weeks before enrollment
• Participation in a clinical trial in onco-hematology
• Patients with myelodysplasia
• Patients with more than one active malignancy at the time of enrollment